{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:03:44Z","timestamp":1789473824274,"version":"build-2803163510"},"reference-count":66,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","award":["H30MC24045"],"award-info":[{"award-number":["H30MC24045"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2023,12,2]]},"DOI":"10.1080\/14712598.2023.2282138","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T13:49:59Z","timestamp":1699969799000},"page":"1173-1184","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7050-0020","authenticated-orcid":false,"given":"Tro","family":"Sekayan","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California, San Diego, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4852-4703","authenticated-orcid":false,"given":"Dana H.","family":"Simmons","sequence":"additional","affiliation":[{"name":"Capitol Scientific, Washington DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9426-6322","authenticated-orcid":false,"given":"Annette","family":"von Drygalski","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California, San Diego, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"World Federation of Hemophilia. Report on the annual global survey 2021 [updated Oct 2022; cited 2023 Apr 29]. Available from: https:\/\/www1.wfh.org\/publications\/files\/pdf-2324.pdf"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13998"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12672"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-050435"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14114"},{"key":"#cr-split#-e_1_3_5_8_1.1","unstructured":"US Food and Drug Administration. Press Release. FDA approves first gene therapy to treat adults with hemophilia B [updated 2022 Nov 22"},{"key":"#cr-split#-e_1_3_5_8_1.2","unstructured":"cited 2023 Jun 22]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-treat-adults-hemophilia-b"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14201"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-528414"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305074"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-669234"},{"key":"e_1_3_5_15_1","unstructured":"Rebinyn\u00ae Prescribing Information. Novo Nordisk Inc. Plainsboro NJ [updated Aug 2022; cited 2023 Oct 22]. Available from: https:\/\/www.novo-pi.com\/rebinyn.pdf"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240896"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14315"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.239160"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14272"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18495"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3847"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006403"},{"key":"#cr-split#-e_1_3_5_23_1.1","unstructured":"Hemophilia Federation of America. Press Release. FDA issues response to novo Nordisk's request for concizumab approval [updated 2023 May 11"},{"key":"#cr-split#-e_1_3_5_23_1.2","unstructured":"cited 2023 Jun 22]. Available from: https:\/\/www.hemophiliafed.org\/fda-issues-crl-for-novo-nordisks-concizumab\/#:~:text=Recently%20Novo%20Nordisk%20received%20a with%20inhibitors%20in%20August%202022"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01912-6"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00284-2"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00037-6"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615621"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3296"},{"issue":"11","key":"e_1_3_5_29_1","first-page":"154a","article-title":"Immune responses to AAV and to factor IX in a phase I study of AAV-mediated liver-directed gene transfer for hemophilia B","volume":"102","author":"High KA","year":"2003","unstructured":"High KA, Manno CS, Sabatino DE, et al. Immune responses to AAV and to factor IX in a phase I study of AAV-mediated liver-directed gene transfer for hemophilia B. Blood. 2003;102(11):154a\u2013155a.","journal-title":"Blood"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108046"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407309"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118334"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000388"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904377"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.09.005"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-804419"},{"key":"e_1_3_5_37_1","unstructured":"EudraLex. European Commission for Public Health. Good manufacturing practice (GMP) guidelines. Volume 4 [cited 2023 May 7]. Available from: https:\/\/health.ec.europa.eu\/medicinal-products\/eudralex\/eudralex-volume-4_en"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep01832"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2009.182"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12177"},{"key":"e_1_3_5_41_1","article-title":"Five year data confirms stable FIX expression and sustained reductions in bleeding and factor IX use following AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B [abstract]","volume":"5","author":"Miesbach W","year":"2021","unstructured":"Miesbach W, Meijer K, Coppens M, et al. Five year data confirms stable FIX expression and sustained reductions in bleeding and factor IX use following AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B [abstract]. Res Pract Thromb Haemost. 2021;5. https:\/\/abstracts.isth.org\/abstract\/five-year-data-confirms-stable-fix-expression-and-sustained-reductions-in-bleeding-and-factor-ix-use-following-amt-060-gene-therapy-in-adults-with-severe-or-moderate-severe-hemophilia-b\/","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000811"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008886"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211644"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1089\/hgtb.2015.037"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.05.009"},{"key":"e_1_3_5_47_1","unstructured":"Alprolix\u00ae Prescribing Information. Sanofi. Waltham: MA [updated 2023 May; cited 2023 Oct 25]. Available from: https:\/\/products.sanofi.us\/Alprolix\/alprolix.html"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14778"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007435"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15281"},{"issue":"1","key":"e_1_3_5_51_1","article-title":"One-stage versus chromogenic factor IX activity in haemophilia B [abstract]","volume":"4","author":"Truedsson \u00c5","year":"2020","unstructured":"Truedsson \u00c5, Schmidt DE, Str\u00e5lfors A, et al. One-stage versus chromogenic factor IX activity in haemophilia B [abstract]. Res Pract Thromb Haemost. 2020 Accessed May 31, 2023; 4(Suppl 1). Available from: https:\/\/abstracts.isth.org\/abstract\/one-stage-versus-chromogenic-factor-ix-activity-in-haemophilia-b\/","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009876"},{"key":"#cr-split#-e_1_3_5_53_1.1","unstructured":"Cision PR Newswire. Press Release. Marburg Germany. First gene therapy for hemophilia B CSL's Hemgenix\u00ae approved by the European Commission [updated 2023 Feb 20"},{"key":"#cr-split#-e_1_3_5_53_1.2","unstructured":"cited 2023 Jun 22]. Available from: https:\/\/newsroom.csl.com\/2023-02-20-First-Gene-Therapy-for-Hemophilia-B -CSLs-HEMGENIX-R- -Approved-by-the-European-Commission"},{"key":"#cr-split#-e_1_3_5_54_1.1","unstructured":"Pharmafile. Press Release. Haywards Heath England. MHRA grants conditional marketing authorization in Great Britain to CSL's Hemgenix\u00ae (etranacogene dezaparvovec) as first gene therapy for haemophilia B [updated 2023 Mar 27"},{"key":"#cr-split#-e_1_3_5_54_1.2","unstructured":"cited 2023 Jun 22]. Available from: https:\/\/pharmafile.com\/news\/mhra-grants-conditional-marketing-authorisation-great-britain-csl-s-hemgenix-etranacogene-de\/"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150541"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2133492"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2022.05.001"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.03.004"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.2147\/PHMT.S293246"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.08.031"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.06.004"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00615-4"},{"issue":"1","key":"e_1_3_5_63_1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2478\/jhp-2022-0021","article-title":"The journey of gene therapy in haemophilia \u2013 putting the patient at the centre of the hub and spoke model","volume":"9","author":"Noone D","year":"2023","unstructured":"Noone D, Astermark J, O\u2019Mahony B, et al. The journey of gene therapy in haemophilia \u2013 putting the patient at the centre of the hub and spoke model. J Haemophil Pract. 2023;9(1):156\u2013166.","journal-title":"J Haemophil Pract"},{"key":"e_1_3_5_64_1","unstructured":"Hemgenix\u00ae Prescribing Information. CSL Behring LLC. King Of Prussia PA [updated 2022 Nov; cited 2023 Oct 25]. Available from: https:\/\/labeling.cslbehring.com\/PI\/US\/Hemgenix\/EN\/Hemgenix-Prescribing-Information.pdf"}],"updated-by":[{"DOI":"10.1080\/14712598.2024.2338643","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000}}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2023.2282138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T19:31:50Z","timestamp":1727206310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2023.2282138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":66,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,2]]}},"alternative-id":["10.1080\/14712598.2023.2282138"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2023.2282138","relation":{"correction":[{"id-type":"doi","id":"10.1080\/14712598.2024.2338643","asserted-by":"object"}]},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-08-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}